Chemotherapy-related cognitive impairment, often called "chemobrain," affects attention, memory, processing speed, and executive function for many people during and after cancer treatment. The condition matters because cognitive changes can impair work, social roles, and quality of life, and because mechanisms are complex: direct neurotoxic effects of cytotoxic agents, inflammation, vascular injury, hormonal changes, sleep disturbance, and psychological stress all contribute. Neuroimaging work by Susan K. Kesler at Stanford University School of Medicine links structural and functional brain changes to cognitive symptoms in breast cancer survivors, supporting a biological substrate for complaints often dismissed as purely psychological.
Evidence for nonpharmacologic approaches
A growing body of research evaluates integrative therapies that aim to reduce symptom burden through behavioral, physical, or mind-body means. Exercise interventions, examined by Michelle C. Janelsins at Wake Forest School of Medicine, show consistent associations with improved self-reported cognition and objective measures in some trials, likely through mechanisms such as reduced inflammation, improved cerebral blood flow, and enhanced neurogenesis. Cognitive rehabilitation and computerized cognitive training target compensatory strategies and neural plasticity, with systematic reviews reporting modest improvements in tested cognitive domains and everyday functioning.
Mind-body and complementary modalities
Mindfulness-based stress reduction and meditation programs have demonstrated benefits for perceived cognitive function and mood in cancer populations, with Leorey N. Saligan at the National Institutes of Health noting links between reduced stress reactivity and better cognitive outcomes. Acupuncture and certain nutritional supplements have more limited and heterogeneous evidence; some trials report symptom relief while others do not replicate effects, leaving clinical recommendations cautious. Cultural context matters, as acceptance of, access to, and adherence with integrative therapies vary by community, insurance coverage, and local availability of trained practitioners.
Consequences of adopting integrative therapies include potential improvements in daily functioning, reduced reliance on medications with adverse effects, and empowerment through self-management. Risks are generally low when interventions are supervised and integrated with oncology care, but safety considerations such as exercise intensity with hematologic compromise or herb-drug interactions must be addressed by oncology teams. Clinical guidance emphasizes multimodal care tailored to the individual, combining physical activity, cognitive training, psychological support, and symptom management.
Overall, integrative therapies are not a cure for chemotherapy-related cognitive impairment but offer evidence-supported, low-risk strategies to mitigate symptoms and restore function. Ongoing research and multidisciplinary clinical pathways are needed to refine which combinations work best for specific patient groups and to ensure equitable access across diverse populations.